Abstract

Problem: Many cancer survivors continue to report distressing and debilitating cognitive problems and fatigue long after treatment has ended. There is a need for evidence-based therapies to manage post-cancer cognitive impairment (PCCI). Neurofeedback is a technology that measures a person's brainwaves and provides feedback to the brain about its own functioning, reminding the brain to self-regulate to improve efficiency, flexibility, and resilience. However, there is a need for a sensitive objective measure of cognitive function to corroborate positive subjective findings of neurofeedback for cancer survivors. VoxNeuroTM provides an objective, quantifiable measurement of brain function by pairing validated neuropsychological tests with EEG results.

Objective: The purpose of this pilot study was to assess feasibility and sensitivity of VoxNeuro as an objective measure of cognitive function in cancer survivors.

Methods: This study used a quasi-experimental pre-test post-test design. Baseline assessment was followed by 20 NeurOptimal sessions over 10 weeks. Objective measures of cognition used VoxNeuro. Subjective measures of cognition used the FACT-Cognition scale.

Results: The VoxNeuro cognitive assessments were both feasible and acceptable to implement with cancer survivors as demonstrated by high completion rates. Participants displayed average cognitive scores that did not change significantly following the neurofeedback intervention as measured by the VoxNeuro. Subjective measures demonstrated significant improvements that were not correlated by the VoxNeuro objective measures.

Conclusions: Results support the feasibility and acceptability of using VoxNeuro cognitive health assessments to measure cognition in cancer survivors; however, VoxNeuro objective scores of cognition did not correlate with subjective measures of cognition in this small sample. Thus, it is not possible to recommend the use of VoxNeuro as an objective measure of cognition in research with cancer survivors. Additional studies with a larger sample size would need to be conducted to confirm or refute our results, which would require greater levels of funding.

Description

Dr. Luctkar-Flude was the recipient of a Sigma/Canadian Nurses Foundation Grant.

Author Details

Marian Luctkar-Flude, RN, PhD, CCSNE, FCNEI: mfl1@queensu.ca; Jane Tyerman, RN, PhD, CCSNE; Sarah Walker, RN, MNSc, PhD(student)

Sigma Membership

Lambda Pi at-Large

Lead Author Affiliation

Queen's University, Kingston, Ontario, Canada

Type

Report

Format Type

Text-based Document

Study Design/Type

Quasi-Experimental Study, Other

Research Approach

Pilot/Exploratory Study

Keywords:

Neurofeedback, Cognitive Impairment, Cognitive Assessment, Cancer Survivors

Rights Holder

All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.

All permission requests should be directed accordingly and not to the Sigma Repository.

All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.

Review Type

None: Sigma Grant Recipient Report

Acquisition

Self-submission

Date of Issue

2024-03-28

Full Text of Presentation

wf_yes

Additional Files

download (1206 kB)

Share

COinS